UA110632C2 - Цирковірус свиней 2 типу (цвс2), імуногенна композиція, що містить його, набір для аналізу та їх застосування - Google Patents
Цирковірус свиней 2 типу (цвс2), імуногенна композиція, що містить його, набір для аналізу та їх застосування Download PDFInfo
- Publication number
- UA110632C2 UA110632C2 UAA201309034A UAA201309034A UA110632C2 UA 110632 C2 UA110632 C2 UA 110632C2 UA A201309034 A UAA201309034 A UA A201309034A UA A201309034 A UAA201309034 A UA A201309034A UA 110632 C2 UA110632 C2 UA 110632C2
- Authority
- UA
- Ukraine
- Prior art keywords
- strain
- tsvs2
- cvs2
- antigen
- porcine circovirus
- Prior art date
Links
- 241001673669 Porcine circovirus 2 Species 0.000 title claims abstract description 26
- 239000000203 mixture Substances 0.000 title claims abstract description 24
- 238000004458 analytical method Methods 0.000 title claims abstract description 23
- 230000002163 immunogen Effects 0.000 title claims abstract description 16
- 239000000427 antigen Substances 0.000 claims description 43
- 102000036639 antigens Human genes 0.000 claims description 43
- 108091007433 antigens Proteins 0.000 claims description 43
- 241000700605 Viruses Species 0.000 claims description 40
- 241000282898 Sus scrofa Species 0.000 claims description 31
- 239000002671 adjuvant Substances 0.000 claims description 27
- 150000007523 nucleic acids Chemical group 0.000 claims description 26
- 241000282887 Suidae Species 0.000 claims description 24
- 208000015181 infectious disease Diseases 0.000 claims description 19
- 239000002773 nucleotide Substances 0.000 claims description 14
- 125000003729 nucleotide group Chemical group 0.000 claims description 14
- 230000003612 virological effect Effects 0.000 claims description 11
- 238000001514 detection method Methods 0.000 claims description 10
- 230000000120 cytopathologic effect Effects 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 9
- 108091033319 polynucleotide Proteins 0.000 claims description 8
- 102000040430 polynucleotide Human genes 0.000 claims description 8
- 239000002157 polynucleotide Substances 0.000 claims description 8
- 241000701093 Suid alphaherpesvirus 1 Species 0.000 claims description 7
- 230000001717 pathogenic effect Effects 0.000 claims description 7
- 230000036039 immunity Effects 0.000 claims description 6
- 241000702619 Porcine parvovirus Species 0.000 claims description 5
- 241000204031 Mycoplasma Species 0.000 claims description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 4
- 230000002238 attenuated effect Effects 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 230000002779 inactivation Effects 0.000 claims description 3
- 229920001184 polypeptide Polymers 0.000 claims description 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 3
- 208000011580 syndromic disease Diseases 0.000 claims description 3
- 208000000655 Distemper Diseases 0.000 claims description 2
- 244000068988 Glycine max Species 0.000 claims description 2
- 235000010469 Glycine max Nutrition 0.000 claims description 2
- 241000725681 Swine influenza virus Species 0.000 claims description 2
- 230000009471 action Effects 0.000 claims description 2
- 230000001850 reproductive effect Effects 0.000 claims description 2
- 230000000241 respiratory effect Effects 0.000 claims description 2
- 230000035939 shock Effects 0.000 claims 2
- 240000005220 Bischofia javanica Species 0.000 claims 1
- 235000010893 Bischofia javanica Nutrition 0.000 claims 1
- 206010010071 Coma Diseases 0.000 claims 1
- 241001026509 Kata Species 0.000 claims 1
- 241000087799 Koma Species 0.000 claims 1
- 241000408551 Meza Species 0.000 claims 1
- 101100498160 Mus musculus Dach1 gene Proteins 0.000 claims 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 claims 1
- 235000011613 Pinus brutia Nutrition 0.000 claims 1
- 241000018646 Pinus brutia Species 0.000 claims 1
- 241000514450 Podocarpus latifolius Species 0.000 claims 1
- 241000435574 Popa Species 0.000 claims 1
- 241000125945 Protoparvovirus Species 0.000 claims 1
- 240000001987 Pyrus communis Species 0.000 claims 1
- 238000009987 spinning Methods 0.000 claims 1
- 101150010802 CVC2 gene Proteins 0.000 abstract 4
- 210000004027 cell Anatomy 0.000 description 52
- 238000003752 polymerase chain reaction Methods 0.000 description 30
- 210000002966 serum Anatomy 0.000 description 28
- 229940031551 inactivated vaccine Drugs 0.000 description 22
- 239000002953 phosphate buffered saline Substances 0.000 description 22
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 21
- 238000002649 immunization Methods 0.000 description 21
- 230000003053 immunization Effects 0.000 description 21
- 125000003275 alpha amino acid group Chemical group 0.000 description 20
- 206010058874 Viraemia Diseases 0.000 description 18
- 108020004707 nucleic acids Proteins 0.000 description 17
- 102000039446 nucleic acids Human genes 0.000 description 17
- 239000000243 solution Substances 0.000 description 16
- 229960005486 vaccine Drugs 0.000 description 15
- 241001465754 Metazoa Species 0.000 description 14
- 241000699670 Mus sp. Species 0.000 description 14
- 241001533384 Circovirus Species 0.000 description 13
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 12
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 12
- 108700026244 Open Reading Frames Proteins 0.000 description 12
- 235000014113 dietary fatty acids Nutrition 0.000 description 12
- 239000000194 fatty acid Substances 0.000 description 12
- 229930195729 fatty acid Natural products 0.000 description 12
- 239000000523 sample Substances 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 210000001165 lymph node Anatomy 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 238000004113 cell culture Methods 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- 238000011534 incubation Methods 0.000 description 9
- 108090000565 Capsid Proteins Proteins 0.000 description 8
- 102100023321 Ceruloplasmin Human genes 0.000 description 8
- 241000202347 Porcine circovirus Species 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 238000010790 dilution Methods 0.000 description 7
- 239000012895 dilution Substances 0.000 description 7
- 150000004665 fatty acids Chemical class 0.000 description 7
- 244000052769 pathogen Species 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 238000005070 sampling Methods 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- 238000002255 vaccination Methods 0.000 description 7
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 description 6
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 6
- 208000027697 autoimmune lymphoproliferative syndrome due to CTLA4 haploinsuffiency Diseases 0.000 description 6
- 239000012141 concentrate Substances 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- 239000000839 emulsion Substances 0.000 description 6
- 150000002148 esters Chemical class 0.000 description 6
- 239000012634 fragment Substances 0.000 description 6
- 210000004072 lung Anatomy 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 230000001575 pathological effect Effects 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- -1 fatty acid ester Chemical class 0.000 description 5
- 230000000415 inactivating effect Effects 0.000 description 5
- 239000013642 negative control Substances 0.000 description 5
- 230000002441 reversible effect Effects 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 4
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 4
- 238000003149 assay kit Methods 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 239000013604 expression vector Substances 0.000 description 4
- 230000008595 infiltration Effects 0.000 description 4
- 238000001764 infiltration Methods 0.000 description 4
- 238000010255 intramuscular injection Methods 0.000 description 4
- 239000007927 intramuscular injection Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 235000019786 weight gain Nutrition 0.000 description 4
- 235000019737 Animal fat Nutrition 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- 108020004638 Circular DNA Proteins 0.000 description 3
- 241000928435 Porcine circovirus 1 Species 0.000 description 3
- 108020005202 Viral DNA Proteins 0.000 description 3
- 208000010399 Wasting Syndrome Diseases 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000002051 biphasic effect Effects 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 239000006143 cell culture medium Substances 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000002480 mineral oil Substances 0.000 description 3
- 235000010446 mineral oil Nutrition 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 239000002356 single layer Substances 0.000 description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 description 3
- 239000008158 vegetable oil Substances 0.000 description 3
- 230000004584 weight gain Effects 0.000 description 3
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 101100123850 Caenorhabditis elegans her-1 gene Proteins 0.000 description 2
- 241000710777 Classical swine fever virus Species 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 108010041986 DNA Vaccines Proteins 0.000 description 2
- 230000004544 DNA amplification Effects 0.000 description 2
- 229940021995 DNA vaccine Drugs 0.000 description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 241000188845 Porcine adenovirus Species 0.000 description 2
- 206010037423 Pulmonary oedema Diseases 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 241000709710 Swine vesicular disease virus Species 0.000 description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- VEZXCJBBBCKRPI-UHFFFAOYSA-N beta-propiolactone Chemical compound O=C1CCO1 VEZXCJBBBCKRPI-UHFFFAOYSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 229940046166 oligodeoxynucleotide Drugs 0.000 description 2
- 101150033318 pcm2 gene Proteins 0.000 description 2
- 238000013081 phylogenetic analysis Methods 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 229960000380 propiolactone Drugs 0.000 description 2
- 208000005333 pulmonary edema Diseases 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 239000012723 sample buffer Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 210000004989 spleen cell Anatomy 0.000 description 2
- 229940031626 subunit vaccine Drugs 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- BCHIXGBGRHLSBE-UHFFFAOYSA-N (4-methyl-2-oxochromen-7-yl) dihydrogen phosphate Chemical compound C1=C(OP(O)(O)=O)C=CC2=C1OC(=O)C=C2C BCHIXGBGRHLSBE-UHFFFAOYSA-N 0.000 description 1
- PMJHNEFCWLUZBC-UHFFFAOYSA-N 4-(4-amino-3-methylphenyl)-2,6,6-trimethylcyclohexa-1,3-dien-1-amine Chemical compound CC1=C(N)C(C)(C)CC(C=2C=C(C)C(N)=CC=2)=C1 PMJHNEFCWLUZBC-UHFFFAOYSA-N 0.000 description 1
- ZBQCCTCQUCOXBO-UHFFFAOYSA-N 4-(4-aminophenyl)-2,2,6,6-tetramethylcyclohex-3-en-1-amine Chemical compound CC1(C)C(N)C(C)(C)CC(C=2C=CC(N)=CC=2)=C1 ZBQCCTCQUCOXBO-UHFFFAOYSA-N 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
- 241000283725 Bos Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 241000581652 Hagenia abyssinica Species 0.000 description 1
- 101001000780 Homo sapiens POU domain, class 2, transcription factor 1 Proteins 0.000 description 1
- 241001536374 Indicator indicator Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- 206010025327 Lymphopenia Diseases 0.000 description 1
- 101100027994 Magnaporthe oryzae (strain 70-15 / ATCC MYA-4617 / FGSC 8958) OME1 gene Proteins 0.000 description 1
- 101100259931 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) tba-1 gene Proteins 0.000 description 1
- 102100035593 POU domain, class 2, transcription factor 1 Human genes 0.000 description 1
- 206010033546 Pallor Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 241000634212 Penia Species 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241001135989 Porcine reproductive and respiratory syndrome virus Species 0.000 description 1
- 101710150114 Protein rep Proteins 0.000 description 1
- 101710152114 Replication protein Proteins 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 208000019229 Spleen disease Diseases 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 208000016063 arterial thoracic outlet syndrome Diseases 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000000720 eyelash Anatomy 0.000 description 1
- 238000009313 farming Methods 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 239000006052 feed supplement Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 206010016766 flatulence Diseases 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 150000002327 glycerophospholipids Chemical class 0.000 description 1
- 201000007192 granulomatous hepatitis Diseases 0.000 description 1
- 208000010758 granulomatous inflammation Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 201000008298 histiocytosis Diseases 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000010185 immunofluorescence analysis Methods 0.000 description 1
- 239000003547 immunosorbent Substances 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000005210 lymphoid organ Anatomy 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 231100001023 lymphopenia Toxicity 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229960005030 other vaccine in atc Drugs 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/00061—Methods of inactivation or attenuation
- C12N2750/00063—Methods of inactivation or attenuation by chemical treatment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/10011—Circoviridae
- C12N2750/10021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/10011—Circoviridae
- C12N2750/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/10011—Circoviridae
- C12N2750/10071—Demonstrated in vivo effect
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/01—DNA viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2469/00—Immunoassays for the detection of microorganisms
- G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201061426087P | 2010-12-22 | 2010-12-22 | |
| PCT/CN2011/084277 WO2012083837A1 (zh) | 2010-12-22 | 2011-12-20 | 猪第二型环状病毒、含彼的免疫组合物、检测套组及其应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA110632C2 true UA110632C2 (uk) | 2016-01-25 |
Family
ID=46313165
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UAA201309034A UA110632C2 (uk) | 2010-12-22 | 2011-12-20 | Цирковірус свиней 2 типу (цвс2), імуногенна композиція, що містить його, набір для аналізу та їх застосування |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US9101571B2 (ja) |
| EP (2) | EP2657333B1 (ja) |
| JP (2) | JP2014507124A (ja) |
| KR (1) | KR101740764B1 (ja) |
| CN (1) | CN103314103B (ja) |
| AU (1) | AU2011348702B2 (ja) |
| BR (1) | BR112013015675A2 (ja) |
| DK (1) | DK2657333T3 (ja) |
| EA (1) | EA028376B1 (ja) |
| ES (1) | ES2763327T3 (ja) |
| MX (1) | MX351578B (ja) |
| TW (2) | TWI508974B (ja) |
| UA (1) | UA110632C2 (ja) |
| WO (1) | WO2012083837A1 (ja) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA113192C2 (xx) | 2011-12-06 | 2016-12-26 | Імуногенна композиція проти цирковірусу свиней типу 2 (pcv2) | |
| CN103893750B (zh) * | 2012-12-31 | 2015-11-25 | 普莱柯生物工程股份有限公司 | 一种抗猪伪狂犬病、猪流感疫苗组合物及其应用 |
| WO2014182872A1 (en) | 2013-05-08 | 2014-11-13 | Protatek International, Inc. | Vaccine for pcv2 and mycoplasma |
| WO2015026912A1 (en) | 2013-08-23 | 2015-02-26 | Boehringer Ingelheim Vetmedica, Inc. | Porcine circovirus type 2 (pcv2) subunit vaccine |
| CN104749361B (zh) * | 2015-01-21 | 2017-04-19 | 中国农业科学院哈尔滨兽医研究所 | 猪圆环病毒2型抗原捕获elisa试剂盒 |
| CN105445457B (zh) * | 2015-03-24 | 2017-08-11 | 中国农业科学院哈尔滨兽医研究所 | 检测猪圆环病毒2型Cap蛋白的单克隆抗体及试剂盒 |
| US9944904B2 (en) * | 2015-05-14 | 2018-04-17 | Merial Inc. | Method for porcine circovirus production and PCV2 vaccines |
| CN105606804A (zh) * | 2016-01-20 | 2016-05-25 | 福州大北农生物技术有限公司 | 一种猪圆环病毒灭活疫苗效力检验方法 |
| CN107686833B (zh) * | 2016-04-18 | 2021-02-19 | 华南农业大学 | 一种猪细小病毒毒株及其应用 |
| CA3042584A1 (en) | 2016-11-03 | 2018-05-11 | Boehringer Ingelheim Vetmedica Gmbh | Vaccine against porcine parvovirus and porcine reproductive and respiratory syndrome virus and methods of production thereof |
| BR112019009133A2 (pt) | 2016-11-03 | 2019-07-16 | Boehringer Ingelheim Vetmedica Gmbh | vacina contra o parvovírus suíno |
| CN109206509B (zh) * | 2017-06-29 | 2021-07-20 | 洛阳普泰生物技术有限公司 | 与伪狂犬病病毒gD蛋白结合的单克隆抗体及其应用 |
| CN107308446B (zh) * | 2017-07-14 | 2021-03-23 | 瑞普（保定）生物药业有限公司 | 一种猪圆环病毒2型灭活疫苗的生产方法 |
| CN107227380A (zh) * | 2017-07-26 | 2017-10-03 | 杭州师范大学 | 一种同步检测pcv2和prv感染的引物序列及方法 |
| CN110343670B (zh) * | 2018-04-04 | 2022-08-30 | 普莱柯生物工程股份有限公司 | 表达猪圆环病毒Cap蛋白基因的重组猪伪狂犬病病毒弱毒株、及其制备方法和应用 |
| CN110387355B (zh) * | 2018-04-18 | 2022-08-30 | 普莱柯生物工程股份有限公司 | 表达猪圆环病毒Cap蛋白基因的重组猪伪狂犬病病毒株、疫苗及其制备方法和应用 |
| JP2021527073A (ja) * | 2018-06-11 | 2021-10-11 | セヴァ サンテ アニマレＣｅｖａ Ｓａｎｔｅ Ａｎｉｍａｌｅ | ブタサーコウイルスに対するワクチン接種 |
| CN109468413B (zh) * | 2018-12-14 | 2021-09-10 | 湖南中净生物科技有限公司 | 一种母猪繁殖障碍病原检测引物、试剂盒、病原检测方法和应用 |
| RU2697849C1 (ru) * | 2019-04-26 | 2019-08-21 | Федеральное государственное бюджетное научное учреждение "Всероссийский научно-исследовательский и технологический институт биологической промышленности" (ФГБНУ ВНИТИБП) | Способ диагностики цирковируса свиней |
| CN110041409B (zh) * | 2019-05-07 | 2022-09-06 | 山东省农业科学院畜牧兽医研究所 | 一种突变型猪圆环病毒2型病毒及应用 |
| CN110698542B (zh) * | 2019-09-16 | 2022-03-22 | 长江大学 | 人工改造的猪圆环病毒2型Rep′蛋白、ELISA检测试剂盒及其应用 |
| CN110711202B (zh) * | 2019-10-25 | 2022-08-19 | 湖南农业大学 | Phb2基因或蛋白的抑制剂在制备抗猪圆环病毒2型药物中的应用 |
| FR3120944A1 (fr) | 2021-03-21 | 2022-09-23 | Virbac | Procédé de détermination de l’âge optimum de vaccination de porcelets par mesure d’une teneur en anticorps dans le colostrum de truies au sein d’un élevage |
| CN114317456A (zh) * | 2021-12-15 | 2022-04-12 | 成都史纪生物制药有限公司 | 一种猪圆环病毒2型毒株的灭活方法及猪圆环病毒疫苗 |
| CN115094060B (zh) * | 2022-06-23 | 2024-08-06 | 湖南农业大学 | 基于LAMP-CRISPR/Cas12a可视化检测PCV2核酸的试剂盒及方法 |
| CN115947794A (zh) * | 2022-07-19 | 2023-04-11 | 沈阳农业大学 | 一种pcv2 orf3特异性多肽及应用 |
| CN116813718B (zh) * | 2023-08-30 | 2023-10-27 | 北京瑞阳瑞泰生物科技有限公司 | 一种重组猪圆环病毒2型Cap蛋白三聚体及其表达体系和应用 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7192594B2 (en) | 1997-10-03 | 2007-03-20 | Merial Limited | Postweaning multisystemic wasting syndrome and porcine circovirus from pigs |
| US6517843B1 (en) | 1999-08-31 | 2003-02-11 | Merial | Reduction of porcine circovirus-2 viral load with inactivated PCV-2 |
| UA78180C2 (uk) | 1997-10-03 | 2007-03-15 | Меріаль | Кільцевий вірус свині типу ii, вакцини та діагностичні реагенти |
| FR2781159B1 (fr) | 1998-07-06 | 2000-10-06 | Merial Sas | Vaccin circovirus et parvovirus porcin |
| US6391314B1 (en) | 1997-10-03 | 2002-05-21 | Merial | Porcine circoviruses vaccines diagnostic reagents |
| US7211379B2 (en) | 1997-10-03 | 2007-05-01 | Merial Sas | Prevention of myocarditis, abortion and intrauterine infection associated with porcine circovirus-2 |
| US20040062775A1 (en) | 1997-12-05 | 2004-04-01 | Agence Francaise De Securite Sanitaire Des Aliments | Circovirus sequences associated with piglet weight loss disease (PWD) |
| FR2772047B1 (fr) | 1997-12-05 | 2004-04-09 | Ct Nat D Etudes Veterinaires E | Sequence genomique et polypeptides de circovirus associe a la maladie de l'amaigrissement du porcelet (map), applications au diagnostic et a la prevention et/ou au traitement de l'infection |
| US6943152B1 (en) | 1999-06-10 | 2005-09-13 | Merial | DNA vaccine-PCV |
| US6497883B1 (en) | 1999-06-10 | 2002-12-24 | Merial | Porcine circovirus recombinant poxvirus vaccine |
| US20030096377A1 (en) * | 2001-06-28 | 2003-05-22 | Virginia Tech Intellectual Properties, Inc. | Differential PCR-RFLP assay for detecting and distinguishing between nonpathogenic PCV-1 and pathogenic PCV-2 |
| US7279166B2 (en) | 2001-12-12 | 2007-10-09 | Virginia Tech Intellectual Properties, Inc. | Chimeric infectious DNA clones, chimeric porcine circoviruses and uses thereof |
| US7276353B2 (en) | 2001-12-12 | 2007-10-02 | Virginia Tech Intellectual Properties, Inc. | Chimeric infectious DNA clones, chimeric porcine circoviruses and uses thereof |
| MX338626B (es) | 2005-12-29 | 2016-04-26 | Boehringer Ingelheim Vetmed | Uso de una composicion inmunogenica de pcv2 para producir los sintomas clinicos en cerdos. |
| EP1941903A1 (en) * | 2007-01-03 | 2008-07-09 | Boehringer Ingelheim Vetmedica Gmbh | Prophylaxis and treatment of PRDC |
| CN101980720A (zh) * | 2008-01-23 | 2011-02-23 | 贝林格尔.英格海姆维特梅迪卡有限公司 | Pcv2猪肺炎支原体致免疫组合物及其制备方法 |
| CN101343671A (zh) * | 2008-08-25 | 2009-01-14 | 湖南省兽医总站 | 猪2型圆环病毒pcr快速检测试剂盒 |
| TWI367256B (en) * | 2008-10-07 | 2012-07-01 | Academia Sinica | Vaccine composition and kit providing protective immunity against porcine circovirus 2 |
| EA201100862A1 (ru) * | 2008-11-28 | 2012-01-30 | Сева Санте Анималь | Новый изолят свиного цирковируса типа 2b и его применения |
| CN101549155B (zh) * | 2009-05-27 | 2012-05-09 | 福州大北农生物技术有限公司 | 猪圆环病毒ⅱ型灭活疫苗及其制备方法 |
| UA113192C2 (xx) * | 2011-12-06 | 2016-12-26 | Імуногенна композиція проти цирковірусу свиней типу 2 (pcv2) |
-
2011
- 2011-12-14 TW TW103118244A patent/TWI508974B/zh active
- 2011-12-14 TW TW100146224A patent/TWI442935B/zh active
- 2011-12-20 ES ES11851859T patent/ES2763327T3/es active Active
- 2011-12-20 MX MX2013007211A patent/MX351578B/es active IP Right Grant
- 2011-12-20 JP JP2013545025A patent/JP2014507124A/ja active Pending
- 2011-12-20 WO PCT/CN2011/084277 patent/WO2012083837A1/zh active Application Filing
- 2011-12-20 EP EP11851859.6A patent/EP2657333B1/en active Active
- 2011-12-20 KR KR1020137019260A patent/KR101740764B1/ko active IP Right Grant
- 2011-12-20 DK DK11851859T patent/DK2657333T3/da active
- 2011-12-20 EA EA201370140A patent/EA028376B1/ru unknown
- 2011-12-20 US US13/332,269 patent/US9101571B2/en active Active
- 2011-12-20 EP EP19196163.0A patent/EP3604504A1/en not_active Withdrawn
- 2011-12-20 AU AU2011348702A patent/AU2011348702B2/en active Active
- 2011-12-20 CN CN201180061073.6A patent/CN103314103B/zh active Active
- 2011-12-20 UA UAA201309034A patent/UA110632C2/uk unknown
- 2011-12-20 BR BR112013015675-9A patent/BR112013015675A2/pt not_active Application Discontinuation
-
2015
- 2015-07-02 US US14/790,462 patent/US9770501B2/en active Active
- 2015-10-23 JP JP2015208806A patent/JP6150864B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US9101571B2 (en) | 2015-08-11 |
| BR112013015675A2 (pt) | 2020-10-06 |
| AU2011348702A1 (en) | 2013-07-18 |
| JP2014507124A (ja) | 2014-03-27 |
| US20120164170A1 (en) | 2012-06-28 |
| EP3604504A1 (en) | 2020-02-05 |
| WO2012083837A1 (zh) | 2012-06-28 |
| EA201370140A1 (ru) | 2013-10-30 |
| DK2657333T3 (da) | 2019-12-09 |
| KR101740764B1 (ko) | 2017-05-26 |
| EP2657333B1 (en) | 2019-10-02 |
| CN103314103B (zh) | 2015-06-24 |
| EA028376B1 (ru) | 2017-11-30 |
| EP2657333A1 (en) | 2013-10-30 |
| AU2011348702B2 (en) | 2016-06-16 |
| EP2657333A4 (en) | 2014-11-12 |
| KR20130098430A (ko) | 2013-09-04 |
| JP6150864B2 (ja) | 2017-06-21 |
| TWI508974B (zh) | 2015-11-21 |
| US9770501B2 (en) | 2017-09-26 |
| MX351578B (es) | 2017-10-19 |
| US20150297709A1 (en) | 2015-10-22 |
| TW201225975A (en) | 2012-07-01 |
| TWI442935B (zh) | 2014-07-01 |
| CN103314103A (zh) | 2013-09-18 |
| JP2016052313A (ja) | 2016-04-14 |
| ES2763327T3 (es) | 2020-05-28 |
| TW201437226A (zh) | 2014-10-01 |
| MX2013007211A (es) | 2014-03-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA110632C2 (uk) | Цирковірус свиней 2 типу (цвс2), імуногенна композиція, що містить його, набір для аналізу та їх застосування | |
| Ju et al. | Immunogenicity of a recombinant pseudorabies virus expressing ORF1–ORF2 fusion protein of porcine circovirus type 2 | |
| CN102065890B (zh) | 嵌合体猪圆环病毒PCV2Gen-1Rep及其用途 | |
| CN110387355B (zh) | 表达猪圆环病毒Cap蛋白基因的重组猪伪狂犬病病毒株、疫苗及其制备方法和应用 | |
| ES2655013T3 (es) | Proteínas sintéticas de la cápside y usos de las mismas | |
| CN109125719A (zh) | 一种含猪圆环病毒3型、猪圆环病毒2型抗原的免疫原性组合物及其应用 | |
| CN104059889B (zh) | 伪狂犬病病毒变异株双基因缺失毒株及其构建方法和应用 | |
| Bhuyan et al. | The construction of recombinant Lactobacillus casei expressing BVDV E2 protein and its immune response in mice | |
| Liu et al. | Recombinant invasive Lactobacillus plantarum expressing the J subgroup avian leukosis virus Gp85 protein induces protection against avian leukosis in chickens | |
| CN109010818A (zh) | 一种预防和/或治疗猪圆环病毒感染的二联疫苗组合物及其制备方法和应用 | |
| KR102239927B1 (ko) | 불활화된 소 로타바이러스를 함유하는 백신 조성물 | |
| CN110343670B (zh) | 表达猪圆环病毒Cap蛋白基因的重组猪伪狂犬病病毒弱毒株、及其制备方法和应用 | |
| US11090378B2 (en) | Porcine parainfluenza virus compositions and related methods | |
| CN106497951B (zh) | 一种VP2融合基因、重组狂犬病病毒rHEP-rVP2株、构建方法及其应用 | |
| KR102365039B1 (ko) | 부유세포 배양에 적응된 A/ASIA/Sea-97 유전형 구제역 바이러스 백신주 및 이의 제조방법 | |
| WO2022026534A1 (en) | Sars-cov-2 immunogenic compositions and methods for protecting against sars-cov-2 clinical signs | |
| CN105505937B (zh) | 抗猪瘟病毒感染的siRNA及其应用 | |
| CN105671046B (zh) | 抗猪瘟病毒感染的siRNA及其应用 | |
| WO2022246449A1 (en) | Sars-coronavirus 2 (sars-cov-2) spike protein subunit vaccines |